Company intelligence / Profile preview

Strongbridge Dublin

Dublin, Ireland

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Strongbridge Biopharma was a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare endocrine and neuromuscular diseases. The company's portfolio included Recorlev (levoketoconazole) for the treatment of endogenous Cushing's syndrome and Keveyis (dichlorphenamide) for primary periodic paralysis. Strongbridge was headquartered in Dublin, Ireland, and maintained a significant presence in the United States. In October 2021, the company was acquired by Xeris Biopharma Holdings, creating a diversified rare disease company.

Therapeutic areas: NeurologyEndocrinology
Modalities: Small moleculePeptides
Industry: Biotech

Partnerships

Novo NordiskAntisense Therapeutics

Beyond the preview

Go deeper on Strongbridge Dublin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Strongbridge Dublin.

Explore the full profile